Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.
Clinical studies demonstrate differences in interferon-beta (IFNbeta) antibody detection frequencies among multiple sclerosis patients receiving different IFNbeta products. We sought to determine if these differences are also found when IFNbeta antibodies are measured in a reference laboratory, where factors normally controlled in clinical studies are unknown. Serum IFNbeta binding antibodies (BAbs) were quantitated by ELISA; BAbs-positive samples were then tested in a bioassay for neutralizing antibodies (NAbs). Consistent with clinical studies, frequencies of BAbs-positive sera and NAbs-positive sera were lower in the Avonex (IFNbeta-1a) treatment group than Rebif (IFNbeta-1a) and Betaseron (IFNbeta-1b) groups. We further identified a predictive relationship between positive BAbs levels and NAbs activity in patients treated with IFNbeta-1a products, but not those treated with IFNbeta-1b.
Prince
Harry E
HE
Focus Diagnostics, 5785 Corporate Avenue, Cypress, CA 90630, USA. hprince@focusdx.com
Lapé-Nixon
Mary
M
Audette
Carol
C
Van Horn
Kenneth
K
D000906:Antibodies / Q000032:analysis* / Q000097:blood / Q000276:immunology*; D001681:Biological Assay / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000276:immunology*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011237:Predictive Value of Tests; D011485:Protein Binding / Q000276:immunology; D012680:Sensitivity and Specificity
D000906:Antibodies; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a